Pathways to quality inpatient management of hyperglycemia and diabetes: A call to action

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 1807-1814

  Draznin, Boris ^a   Gilden, Janice ^b   Golden, Sherita H ^c   Inzucchi, Silvio E ^d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; DEXAMETHASONE; GLUCOCORTICOID; GLUCOSE; INCRETIN; INSULIN; ISOPHANE INSULIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; PREDNISONE; STEROID;

CARDIOVASCULAR MORTALITY; CONTINUOUS INFUSION; DIABETES MELLITUS; ENTERIC FEEDING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAFT SURVIVAL; HEALTH CARE MANAGEMENT; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH ECONOMICS; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; INTERPERSONAL COMMUNICATION; NEW ONSET DIABETES AFTER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; ORGAN TRANSPLANTATION; OUTPATIENT CARE; PARENTERAL NUTRITION; PATIENT CARE; POINT OF CARE TESTING; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STANDARDIZATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INPATIENTS;

EID: 84885991431     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2508     Document Type: Review

References (55)

1. Sodi-Pallares D, TestelliMR, Fishleder BL, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 1962;9:166-181
2. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65
3. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternalwound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352-360; discussion 360-362
4. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients.NEngl JMed 2001;345:1359-1367
5. Brunkhorst FM, Engel C, Bloos F, et al.; German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139
6. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009;35:1738-1748
7. Finfer S, Chittock DR, Su SY, et al.; NICESUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297
8. Moghissi ES, Korytkowski MT, DiNardo M, et al.; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32:1119-1131
9. QaseemA,Humphrey LL,Chou R, SnowV, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011;154:260-267
10. Umpierrez GE, Hellman R, Korytkowski MT, et al.; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012;97:16-38
11. Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med 2012;40:3251-3276
12. Simmons D, Wenzel H. Diabetes inpatients: a case of lose, lose, lose. Is it time to use a 'diabetes-attributable hospitalization cost' to assess the impact of diabetes? Diabet Med 2011;28:1123-1130
13. Clement S, Braithwaite SS, Magee MF, et al.; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27: 553-591
14. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patientcentered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care2012;35:1364-1379
15. Braithwaite SS, Magee M, Sharretts JM, Schnipper JL, Amin A, Maynard G; Society of Hospital Medicine Glycemic Control Task Force. The case for supporting inpatient glycemic control programs now: the evidence and beyond. J Hosp Med 2008;3(Suppl):6-16
16. Barnard K, Batch B, Lien LF. Subcutaneous insulin: a guide for dosing regimens in the hospital. Glycemic Control in the Hospitalized Patient. 1st ed. Lien LF, Cox ME, Feinglos MN, Corsino L, Eds. New York, Springer, 2011, p. 7-16
17. Garber AJ, Moghissi ES, Bransome ED Jr, et al.; American College of Endocrinology Task Force on Inpatient Diabetes Metabolic Control. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 2004; 10(Suppl. 2):4-9
18. Munoz M, Pronovost P, Dintzis J, et al. Implementing and evaluating a multicomponentinpatient diabetes management program: putting research into practice. Jt Comm J Qual Patient Saf 2012;38:195-206
19. McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am 2012;41: 175-201
20. Goldberg PA, Bozzo JE, Thomas PG, et al. "Glucometrics" dassessing the quality of inpatient glucose management. Diabetes Technol Ther 2006;8:560-569
21. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in patients hospitalizedwith acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008;117: 1018-1027
22. Schnipper JL, Magee M, Larsen K, Inzucchi SE, Maynard G; Society of Hospital Medicine Glycemic Control Task Force. Society of Hospital Medicine Glycemic Control Task Force summary: practical recommendations for assessing the impact of glycemic control efforts. J Hosp Med 2008;3(Suppl):66-75
23. Wexler DJ, Meigs JB, Cagliero E, Nathan DM, Grant RW. Prevalence of hyper- and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals. Diabetes Care 2007;30:367-369
24. Hammer MJ, Casper C, Gooley TA, O'Donnell PV, Boeckh M, Hirsch IB. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2009;15:344-351
25. Van den Berghe G, Wouters PJ, Kesteloot K, Hilleman DE. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. Crit Care Med 2006;34:612-616
26. Krinsley JS, Jones RL. Cost analysis of intensive glycemic control in critically ill adult patients. Chest 2006;129:644-650
27. Sadhu AR, Ang AC, Ingram-Drake LA, Martinez DS, Hsueh WA, Ettner SL. Economic benefits of intensive insulin therapy in critically Ill patients: the targeted insulin therapy to improve hospital outcomes (TRIUMPH) project. Diabetes Care 2008;31:1556-1561
28. Hirsch IB. Sliding scale insulindtime to stop sliding. JAMA 2009;301:213-214
29. Schnipper JL, Barsky EE, Shaykevich S, Fitzmaurice G, Pendergrass ML. Inpatient management of diabetes and hyperglycemia among general medicine patients at a large teaching hospital. J Hosp Med 2006; 1:145-150
30. Boord JB, Greevy RA, Braithwaite SS, et al. Evaluation of hospital glycemic control at US academic medical centers. J Hosp Med 2009;4:35-44
31. Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-2186
32. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34:256-261
33. Cheung NW, Napier B, Zaccaria C, Fletcher JP. Hyperglycemia is associated with adverse outcomes in patients receiving total parenteral nutrition.Diabetes Care 2005;28:2367-2371
34. Pasquel FJ, Spiegelman R, McCauley M, et al. Hyperglycemia during total parenteral nutrition: an important marker of poor outcome and mortality in hospitalized patients. Diabetes Care 2010;33: 739-741
35. Korytkowski MT, Salata RJ, Koerbel GL, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care 2009;32:594-596
36. Hsia E, Seggelke SA, Gibbs J, Rasouli N, Draznin B. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy. Nutr Clin Pract 2011;26:714-717
37. Baldwin D, Kinnare K, Draznin B, et al. Insulin treatment of hyperglycemia in hospitalized patients receiving total parenteral nutrition (TPN) (Abstract). Diabetes 2012;61(Suppl. 1):A1070
38. Bevier WC, Zisser HC, Jovanovic L, et al. Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone. J Diabetes Sci Tech 2008;2:578-583
39. Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol 2006;4: 479-483
40. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of longacting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion ofinsulin lispro. Diabetes 2000;49:2142-2148
41. Seggelke SA, Gibbs J, Draznin B. Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. J Hosp Med 2011;6: 175-176
42. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagonlike peptide-1 receptor agonist treatment prevents glucocorticoid- induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011;34:412-417
43. Cosio FG, Pesavento TE,OseiK,HenryML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001;59:732-737
44. Foo SM, Wong HS, Morad Z. Risk factors and incidence of posttransplant diabetes mellitus in renal transplant recipients. Transplant Proc 2004;36:2139-2140
45. Schiel R, Heinrich S, Steiner T, Ott U, Stein G. Post-transplant diabetes mellitus: risk factors, frequency of transplant rejections, and long-term prognosis. Clin Exp Nephrol 2005;9:164-169
46. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-185
47. Lufft V, Dannenberg B, Schlitt HJ, Pichlmayr R, Brunkhorst R. Cardiovascular morbidity and mortality in patients with diabetes mellitus type I after kidney transplantation: a case-control study. Clin Nephrol 2004;61:238-245
48. Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-termtransplant graft and patient survival. Clin J Am Soc Nephrol 2008;3:814-821
49. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010;56:1127-1139
50. Schwartz S, Kohl BA. Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.Diabetes Metab Syndr Obes 2010;3: 227-242
51. Schwartz S, DeFronzo RA. Is incretinbased therapy ready for the care of hospitalized patients with type 2 diabetes? The time has come for GLP-1 receptor agonists! Diabetes Care 2013;36:2107-2111
52. Griffith ML, Boord JB, Eden SK, Matheny ME. Clinical inertia of discharge planning among patients with poorly controlled diabetesmellitus. J Clin Endocrinol Metab 2012;97:2019-2026
53. Stolker JM, Spertus JA, McGuire DK, et al. Relationship between glycosylated hemoglobin assessment and glucose therapy intensification in patients with diabetes hospitalized for acute myocardial infarction. Diabetes Care 2012;35:991-993
54. Wu EQ, Zhou S, Yu A, et al. Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization. Endocr Pract 2012;18:651-659
55. Robbins JM, Webb DA. Diagnosing diabetes and preventing rehospitalizations: the urban diabetes study. Med Care 2006; 44:292-296